How to Compound Low Dose Naltrexone: Capsules vs. Liquid

Low dose naltrexone, commonly called LDN, is compounded in either capsule or liquid form because the commercially available naltrexone tablet comes in a 50 mg dose, far too high for the 0.5 mg to 4.5 mg range that LDN protocols call for. Neither form is inherently superior; the choice depends on dosing flexibility, shelf life, cost, and whether the patient can swallow capsules. The compounding process for each is straightforward in a pharmacy setting, but the details matter more than they might seem, because tiny doses amplify any errors in measurement or mixing.

Why LDN Has to Be Compounded at All

Naltrexone was originally approved as a 50 mg tablet to help manage opioid and alcohol dependence. At that dose, it fully blocks opioid receptors around the clock. LDN works on a different principle: a brief, partial opioid blockade that lasts only a few hours, prompting the body to upregulate its own endogenous opioids and opioid receptors in response. This “rebound” effect has been demonstrated in multiple studies and is thought to underlie LDN’s anti-inflammatory and analgesic properties.¹ Because no manufacturer sells naltrexone in doses below 50 mg, anyone who wants LDN needs a compounding pharmacy to prepare it, whether as a capsule or a liquid.

The lack of a commercial product also means there is no FDA-standardized formulation. Compounding pharmacies follow general guidelines from sources like the United States Pharmacopeia (USP), but individual pharmacies may use slightly different fillers, flavoring agents, or preparation techniques. That variability is one reason patients and prescribers benefit from understanding what goes into each form.

How LDN Capsules Are Made

Capsule compounding starts with naltrexone hydrochloride powder, which is weighed on an analytical balance accurate to fractions of a milligram. The active ingredient is then blended with a filler, often microcrystalline cellulose (sold under the brand name Avicel), using a technique called geometric dilution. In geometric dilution, the pharmacist adds the filler in progressively larger portions, mixing thoroughly at each step. This ensures the tiny amount of naltrexone is distributed as evenly as possible throughout the powder blend. The finished blend is then packed into individual capsules, typically size 3 or size 4 gelatin or vegetarian capsules.²

Quality control for capsules involves several checks: the overall average weight of the batch, individual weight variation from capsule to capsule, whether the capsule shell dissolves properly, whether the contents disintegrate correctly, an assay confirming the active drug content, and a visual inspection for color uniformity and proper locking of the capsule halves.² These steps might sound routine, but at LDN doses they carry outsized importance. When you are putting 1.5 mg or 4.5 mg of drug into a capsule that holds perhaps 200 mg of total powder, the active ingredient makes up only about 1% to 2% of the fill. Any clumping or uneven mixing can mean one capsule has significantly more drug than another.

How Capsule Fillers Affect the Final Product

The choice of filler is not just about bulking up the capsule. Different fillers dissolve at different rates, which affects how quickly the naltrexone is released in the gut. Research on capsule-filling machines has shown that insoluble fillers like dicalcium phosphate tend to slow drug dissolution, especially when the powder is packed tightly. Soluble fillers like lactose or microcrystalline cellulose generally allow faster, more consistent release. Adding a small percentage of a disintegrant, such as croscarmellose sodium, can counteract the slowing effect of compression and improve drug release regardless of the filler used.³

For LDN specifically, microcrystalline cellulose is a common and well-regarded choice. It flows well during encapsulation, compresses without forming hard plugs, and releases the drug readily when it contacts digestive fluids. Some pharmacies use lactose-based fillers, which also work well, though patients with lactose sensitivity occasionally ask for alternatives. If you have a preference or a known sensitivity, it is worth asking your pharmacy what filler they use. Most compounding pharmacies are happy to tell you and can often accommodate a substitution.

How LDN Liquid Is Prepared

The liquid form of LDN is typically made by dissolving naltrexone hydrochloride powder (or, in some cases, crushing commercial 50 mg tablets) into a measured volume of purified water or a flavored vehicle to achieve a known concentration, usually 1 mg per milliliter. At that concentration, a 1.5 mg dose is 1.5 mL and a 4.5 mg dose is 4.5 mL, easy to measure with an oral syringe.

Stability studies on naltrexone oral liquids at 1 mg/mL have found that the drug remains stable when stored in the dark for 60 days at refrigerator temperature and for 30 days at room temperature, with no significant decomposition observed over 90 days in formulations kept refrigerated.⁴ That means liquid LDN should be refrigerated and used relatively quickly compared to capsules. Some pharmacies dispense it in amber bottles to protect against light degradation, which is a reasonable precaution even though the primary stability concern is temperature.

The preparation itself is simpler than capsule compounding in some respects: there is no geometric dilution step, no capsule filling, and no concern about powder uniformity. Once the naltrexone is fully dissolved, the solution is inherently uniform, so every milliliter contains the same amount of drug. That uniformity is one of the liquid form’s genuine advantages.

Stability and Shelf Life

This is where the two forms diverge sharply. Compounded LDN capsules stored at room temperature and protected from light have been shown to retain their labeled potency for a full year, staying within 90% to 110% of the target dose throughout the study period.⁵ That stability data supports a beyond-use date of up to 360 days for capsules, which is unusually long for a compounded medication. In practical terms, a patient can fill a large batch of capsules and use them over many months without worrying about degradation.

Liquid LDN, by contrast, has a much shorter window. At refrigerator temperature, the evidence supports about 60 days of stability; at room temperature, closer to 30 days.⁴ That means patients using the liquid form typically need to refill monthly or bimonthly, depending on storage conditions. If you travel frequently or live somewhere where refrigeration is unreliable, this is a meaningful inconvenience.

The practical upshot: capsules are set-it-and-forget-it, while liquid requires a bit more attention to storage and timing. For patients who are on a stable dose and just want simplicity, capsules usually win on shelf life alone.

Dosing Flexibility

Liquid LDN’s real strength is dose titration. Most LDN protocols start low, often at 0.5 mg or 1 mg, and increase gradually over weeks to a target dose, commonly 4.5 mg. With a liquid at 1 mg/mL, stepping up in 0.5 mg increments is as simple as adjusting the syringe by half a milliliter. No new prescription is needed, no new batch of capsules has to be compounded, and the patient can fine-tune on the fly if side effects appear at a particular dose.

Capsules are fixed-dose by nature. If a patient wants to go from 1.5 mg to 3 mg, the pharmacy has to compound a new batch at the new strength. Some prescribers write for multiple capsule strengths at once (1 mg, 1.5 mg, 3 mg, 4.5 mg) so the patient can step up without waiting for a new order, but this means paying for several batches upfront, and some of those capsules may never be used if the patient settles on a dose quickly.

For patients who are already on a stable maintenance dose and have no plans to change, the dose-flexibility advantage of liquid largely disappears. But for someone just starting LDN or experimenting with the dose that works best for their condition, liquid is considerably more practical.

Cost and Accessibility

Compounded medications are not covered by most insurance plans, so cost comes directly out of pocket. Prices vary widely by pharmacy and by region, but a few general patterns hold. A month’s supply of LDN capsules typically costs somewhere in the range of $30 to $60 at most compounding pharmacies, though some charge more for rush orders or smaller quantities. Liquid preparations can be slightly cheaper per dose because the compounding labor is simpler, but the shorter shelf life means smaller batch sizes, which can offset the savings.

Not every pharmacy compounds LDN. You generally need a compounding pharmacy rather than a standard retail chain, and in rural areas those can be sparse. Many compounding pharmacies now ship nationally, which opens up options but also introduces shipping concerns, especially for liquid formulations that benefit from refrigeration. If your liquid LDN sits in a hot delivery truck for a day, that eats into its already-limited shelf life. Capsules are far less sensitive to shipping conditions.

Some patients make liquid LDN at home by dissolving a commercial 50 mg naltrexone tablet in a measured volume of water. While this is technically possible and sometimes discussed in patient communities, it introduces accuracy and contamination risks that a pharmacy environment is designed to control. Commercial tablets contain binders, coatings, and other inactive ingredients that do not fully dissolve, making it difficult to guarantee a consistent concentration. If you go this route, using pure naltrexone powder rather than crushed tablets produces a cleaner solution, though sourcing pharmaceutical-grade powder as a consumer is its own challenge.

When One Form Clearly Beats the Other

Certain situations make the choice straightforward:

Difficulty swallowing: Children, elderly patients, or anyone with dysphagia will do better with a liquid they can measure into a syringe and take directly or mix into a small amount of juice.
Active titration: If the prescriber wants to adjust the dose frequently, liquid avoids the waste and delay of recompounding capsules at each new strength.
Travel or inconsistent refrigeration: Capsules win here because they are shelf-stable at room temperature for up to a year and do not require cold storage.
Long-term stable dosing: A patient on 4.5 mg daily who has been at that dose for months has no particular reason to use liquid. Capsules are more convenient, last longer, and require fewer refills.
Taste sensitivity: Naltrexone has a bitter taste. Capsules bypass the taste buds entirely, while liquid formulations, even flavored ones, sometimes leave a taste that bothers some patients.

Common Mistakes in LDN Compounding

The most frequent error in capsule compounding is inadequate mixing. Because the active ingredient is such a small fraction of the total fill, rushing the geometric dilution step can produce capsules where some contain almost no drug and others contain a double dose. A well-run pharmacy uses documented mixing times, weighs a sample of finished capsules to check uniformity, and assays the drug content periodically.

For liquids, the biggest pitfall is using the wrong measuring device. A kitchen teaspoon is not a precision instrument. Even a standard measuring cup introduces enough variability at sub-milliliter volumes to meaningfully alter a dose. Oral syringes, which are inexpensive and widely available, are the correct tool. Most pharmacies dispense them alongside the liquid, but if yours does not, ask for one.

Another common issue is storage. Patients sometimes leave liquid LDN on a countertop out of habit, forgetting that it needs refrigeration. At room temperature, the beyond-use date drops to roughly a month, and in warm climates even that may be optimistic. Capsules are more forgiving but should still be kept out of direct sunlight, since light exposure over time can degrade the naltrexone even in solid form.

How LDN’s Mechanism Relates to the Dosing Form

LDN’s therapeutic rationale depends on a brief opioid receptor blockade followed by a rebound in the body’s own opioid signaling. The blockade needs to be temporary, typically lasting only a few hours, rather than the sustained 24-hour blockade produced by the full 50 mg dose. This is why the drug is usually taken at bedtime: the short blockade occurs during sleep, and by morning, the endogenous opioid upregulation is underway.¹

The form of the medication can subtly affect how quickly this blockade kicks in. A liquid formulation is absorbed somewhat faster than a capsule because there is no capsule shell to dissolve and no filler matrix to disperse through. In practice, the difference is usually small and probably clinically insignificant for most patients, since the timing window is broad. But some patients who switch from one form to the other notice slight changes in side effects, particularly the vivid dreams that are a well-known early side effect of LDN. If this happens, it is likely an absorption-speed effect rather than a sign that something is wrong with the preparation.

Research in animal models has also shown that LDN’s intermittent receptor blockade can upregulate specific growth-factor receptors involved in immune regulation, an effect that depends on the drug clearing the system between doses.⁶ Sustained-release formulations, which some patients have asked about, would theoretically undermine this mechanism by keeping blood levels elevated too long. For that reason, both capsule and liquid LDN are designed as immediate-release preparations.

Choosing a Compounding Pharmacy

Not all compounding pharmacies operate at the same quality level. A few things are worth checking before you commit to one. First, look for accreditation from the Pharmacy Compounding Accreditation Board (PCAB) or compliance with USP Chapter 795, which governs non-sterile compounding. These standards require documented procedures for weighing, mixing, quality testing, and assigning beyond-use dates.

Second, ask whether the pharmacy performs potency testing on its LDN batches. Some pharmacies test every batch; others test periodically; a few never test at all. Given how small the doses are, a pharmacy that skips potency testing is asking you to trust its technique on faith. The stability study that established a one-year shelf life for LDN capsules, for example, relied on assay results at regular intervals to confirm the drug stayed within 90% to 110% of the labeled amount.⁵ A pharmacy that does not run similar checks cannot make confident claims about its products.

Third, consider communication. A good compounding pharmacy will tell you exactly what filler they use, what concentration they prepare liquids at, and what beyond-use date they assign. If the pharmacy is vague or dismissive about these details, that is a red flag, not because the staff are necessarily doing anything wrong, but because transparency about compounding practices correlates strongly with overall quality culture. Your prescriber may also have a preferred pharmacy they have worked with before and trust, which can save you the legwork of evaluating options from scratch.

1
PubMed Central. The use of low-dose naltrexone LDN as a novel anti-inflammatory treatment for chronic pain
2
US Pharmacist. Naltrexone Hydrochloride 1.5-mg and 4.5-mg Capsules
3
PubMed. Multiple tamping effects on drug dissolution from capsules filled on a dosing-disk type automatic capsule filling machine
4
PubMed. Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone
5
PubMed. The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia
6
International Immunopharmacology. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy